| abstract |
Controlled release pharmaceutical compositions comprise preferably polyethylene-vinylacetate or poly (lactic-glucolic acid), biocompatible polymer materials with soluble receptors capable of binding their ligands integrated therein and thus have an impact on ligand performance. . The water-soluble receptor is preferably a soluble form of the tumor necrosis factor TNFα receptor. Such compositions are used to treat diseases by neutralizing the deleterious effects of TNFα. |